TAKANASHI KEN 4

4 · Wave Life Sciences Ltd. · Filed Mar 26, 2026

AI-generated summary of this filing

Updated Mar 26, 2026

Wave Life Sciences Director Ken Takanashi Converts Preferred into 3.9M Shares

What Happened

Ken Takanashi, a director of Wave Life Sciences (WVE), reported conversion of 3,901,348 Series A preferred shares into 3,901,348 ordinary shares on March 23, 2026. The conversion price/value is reported as $0.00 (one-for-one conversion), so no cash changed hands. This was a corporate conversion of preferred stock to common stock, not an open‑market buy or sale by the director.

Key Details

Transaction date: March 23, 2026; Form 4 filed: March 26, 2026 (filed one business day after the two-business-day Section 16 deadline).
Reported entries: conversion (acquired) 3,901,348 shares @ $0.00 and conversion (disposed/derivative) 3,901,348 @ $0.00 (conversion of derivative security).
Shares reported as held after the transaction: an aggregate of 9,606,408 shares held by related entities (6,107,593 shares held by SNBL USA and 3,498,815 held by SNBL) per the filing.
Footnotes: SNBL USA, Ltd. and Shin Nippon Biomedical Laboratories, Ltd. elected to convert Series A preferred into ordinary shares one-for-one; processing and time-zone issues delayed confirmation of the effective date. Takanashi is a director of SNBL USA and SNBL and may be deemed to beneficially own the shares held by those entities, but he disclaims beneficial ownership except to the extent of any pecuniary interest.

Context

This was a corporate conversion of preferred stock into common stock (derivative conversion), not a purchase or sale in the market. Such conversions reflect capital-structure changes rather than an insider signaling buy/sell intent.
The filing was submitted on March 26 for a March 23 conversion—note this is one business day later than the standard two-business-day Form 4 filing window under Section 16; the filing cites processing/time-zone issues for the delay.

Form 4

Period: 2026-03-23

Director

Transactions

Conversion
Ordinary Shares
[F1][F2][F3][F4]
2026-03-23+3,901,348→ 9,606,408 total(indirect: See Footnote)
Conversion
Series A Preferred Shares
[F1][F2][F4]
2026-03-23−3,901,348→ 0 total(indirect: See Footnote)
→ Ordinary Shares (3,901,348 underlying)

Holdings

Footnotes (4)

[F1]The sole holder of Wave's Series A preferred shares, SNBL USA, Ltd. ("SNBL USA") and Shin Nippon Biomedical Laboratories, Ltd. ("SNBL"), elected to convert its Series A preferred shares into ordinary shares on a one-for-one basis on March 23, 2026. Due to processing issues among the Issuer's vendors, complicated by the time difference with Singapore, the date of the conversion was not confirmed to be effective until well after March 23, 2026.
[F2]Includes (i) 2,100,000 shares held by SNBL USA and (ii) 1,801,348 shares held by SNBL.
[F3]Includes an aggregate of (i) 6,107,593 shares held by SNBL USA and (ii) 3,498,815 shares held by SNBL.
[F4]Ken Takanashi, a director of the Issuer, is a director of SNBL USA and SNBL and Mr. Takanashi may be deemed to beneficially own the reported securities held by SNBL USA and SNBL. Pursuant to Rule 16a-1 under the Securities Exchange Act of 1934, as amended (the "Act"), Mr. Takanashi disclaims beneficial ownership of the reported securities held by SNBL USA and SNBL, except to the extent of his pecuniary interest therein. The filing of this Form 4 shall not be construed as an admission that Mr. Takanashi is or was for the purposes of Section 16(a) of the Act, or otherwise, the beneficial owner of any of the reported securities held by SNBL USA or SNBL.

Signature

/s/ Ken Takanashi|2026-03-26

1 file